D-glutamate
D-glutamate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn ii | New Drug Application | 2022-05-04 |
| aminosyn-pf | New Drug Application | 2022-07-21 |
| clinisol | ANDA | 2018-06-01 |
| kabiven | New Drug Application | 2023-08-02 |
| perikabiven | New Drug Application | 2023-08-07 |
| plenamine | ANDA | 2023-04-21 |
| premasol - sulfite-free (amino acid) | ANDA | 2022-08-04 |
| prosol | New Drug Application | 2020-10-07 |
| trophamine | New Drug Application | 2023-11-27 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
467 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 10 | 13 | 4 | 5 | 15 | 46 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 7 | 11 | 4 | 2 | 18 | 42 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 7 | 11 | 4 | 3 | 14 | 39 |
| Non-small-cell lung carcinoma | D002289 | — | — | 9 | 20 | 11 | 1 | 1 | 37 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 5 | 5 | 4 | 4 | 5 | 23 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 6 | — | 2 | 4 | 15 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 2 | 4 | 1 | 2 | 5 | 14 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 2 | 9 | — | 1 | 3 | 13 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 7 | — | 1 | 2 | 10 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | 2 | — | 3 | 4 | 10 |
Show 50 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | 4 | 16 | 7 | — | 3 | 27 |
| Healthy volunteers/patients | — | — | — | 13 | 5 | 1 | — | 4 | 21 |
| Carcinoma | D002277 | — | C80.0 | 8 | 7 | 2 | — | — | 14 |
| Syndrome | D013577 | — | — | — | 3 | 2 | — | 7 | 12 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 7 | 2 | — | 3 | 12 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 8 | 2 | — | 2 | 12 |
| Treatment-resistant depressive disorder | D061218 | — | — | 2 | 5 | 1 | — | 3 | 11 |
| Adenocarcinoma | D000230 | — | — | 4 | 6 | 1 | — | — | 10 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 3 | 1 | — | — | 7 |
| Brain injuries | D001930 | — | S06.9 | 1 | 5 | 1 | — | — | 7 |
Show 72 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 3 | 10 | — | — | 2 | 15 |
| Neoplasms | D009369 | — | C80 | 7 | 6 | — | — | 1 | 12 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 8 | — | — | — | 9 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 4 | — | — | 2 | 9 |
| Compulsive personality disorder | D003193 | — | F60.5 | 2 | 6 | — | — | 2 | 8 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 4 | — | — | 2 | 6 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 3 | 1 | — | — | 2 | 6 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | 4 | — | — | — | 5 |
| Melanoma | D008545 | — | — | 3 | 2 | — | — | — | 4 |
| Autism spectrum disorder | D000067877 | — | F84.0 | 1 | 1 | — | — | 2 | 4 |
Show 104 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 2 | 3 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 3 | — | — | — | — | 3 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | 1 | 2 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 2 | — | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | 1 | 2 |
| Positron-emission tomography | D049268 | — | — | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | 2 | — | — | — | — | 2 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | 1 | — | — | — | 1 | 2 |
| Hyperkinesis | D006948 | — | — | 1 | — | — | — | 1 | 2 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burns | D002056 | — | T30.0 | — | — | — | — | 5 | 5 |
| Problem behavior | D000066553 | — | — | — | — | — | — | 2 | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 2 | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | — | 2 | 2 |
| Sars-cov-2 | D000086402 | — | — | — | — | — | — | 2 | 2 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 2 | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 2 | 2 |
| Traumatic stress disorders | D040921 | — | — | — | — | — | — | 2 | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 2 | 2 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | — | — | 2 | 2 |
Show 79 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | D-glutamate |
| INN | — |
| Description | D-glutamic acid is an optically active form of glutamic acid having D-configuration. It has a role as an Escherichia coli metabolite and a mouse metabolite. It is a D-alpha-amino acid and a glutamic acid. It is a conjugate acid of a D-glutamate(1-). It is an enantiomer of a L-glutamic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H](CCC(=O)O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 6893-26-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL76232 |
| ChEBI ID | 15966 |
| PubChem CID | 23327 |
| DrugBank | DB02517 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Aminosyn ii
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
286 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use